Welcome to our dedicated page for TG Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on TG Therapeutics stock.
TG Therapeutics develops and commercializes therapies for B-cell diseases, with news centered on BRIUMVI (ublituximab-xiiy), its anti-CD20 monoclonal antibody for adult patients with relapsing forms of multiple sclerosis. Company updates commonly cover U.S. net product revenue, global revenue targets, commercial demand, and international commercialization economics tied to BRIUMVI.
Recurring developments also include clinical and real-world data for BRIUMVI in relapsing multiple sclerosis, presentations and publications from multiple sclerosis studies, and development work on a subcutaneous formulation. Corporate news includes financing arrangements, share repurchase authorization updates, operating-expense guidance, and business outlook commentary alongside quarterly and annual results.
TG Therapeutics (NASDAQ: TGTX) published a post hoc pooled analysis from Phase 3 ULTIMATE I and II showing BRIUMVI (ublituximab) produced large, statistically significant reductions in relapses and MRI activity versus teriflunomide in people with highly active relapsing MS.
Key results: ARR 0.145 vs 0.496 (70.8% reduction), early and sustained lesion reductions through Week 96, and markedly higher NEDA-3 rates (77.9% vs 16.4% during Weeks 24–96).
TG Therapeutics (NASDAQ: TGTX) announced the schedule of data presentations for BRIUMVI (ublituximab-xiiy) at the American Academy of Neurology (AAN) 2026 annual meeting, April 18–22 in Chicago. Two poster presentations on April 21 cover real-world ENABLE Phase 4 experience and ENHANCE safety/tolerability updates. Abstracts are available on the AAN website and data will be posted to the company publications page.
Precision BioSciences (Nasdaq: DTIL) will receive $7.5 million from TG Therapeutics after a clinical milestone tied to a Phase 1 trial of azer-cel in progressive multiple sclerosis.
The proceeds consist of $5.25 million cash plus $2.25 million via purchase of 201,504 Precision shares at $11.17 per share. Precision said these funds, existing cash, and its ATM access are expected to provide runway through 2028.
TG Therapeutics (NASDAQ: TGTX) reported fourth-quarter 2025 total revenue of $192.6M and full-year 2025 revenue of $616.3M, driven by BRIUMVI U.S. net revenue of $182.7M (Q4) and $594.1M (FY). The company raised 2026 total global revenue guidance to $875–$900M and expects BRIUMVI U.S. revenue of $825–$850M.
Other highlights: completed a $100M repurchase and authorized an additional $100M, presented multi‑year BRIUMVI data, advanced pivotal trials including a subcutaneous program, and ended 2025 with $199.5M cash and investments.
TG Therapeutics (NASDAQ: TGTX) will host a conference call on Thursday, February 26, 2026 at 8:30 AM ET to discuss fourth-quarter and full-year 2025 results and provide a 2026 business outlook.
Michael S. Weiss, Chairman and CEO, will host. A live webcast and a 30-day replay will be available on the company's Investors & Media Events page. Financial results will be issued in a press release prior to the call.
TG Therapeutics (NASDAQ: TGTX) published five-year ULTIMATE I/II open-label extension data in JAMA Neurology showing durable efficacy and consistent safety for BRIUMVI (ublituximab) in relapsing MS.
Key highlights: 3,600+ participant-years exposure, Year‑5 ARR 0.020, >70% on treatment at Year 5, 8% 24‑week CDP with continuous treatment, and no new safety signals.
TG Therapeutics (NASDAQ: TGTX) announced a collaboration with actress Christina Applegate to raise national awareness of multiple sclerosis (MS) and foster honest conversations. The initiative launched during Super Bowl LX and introduced www.NextInMS.com, a platform with Christina’s personal perspectives and expert educational content to support people living with MS.
The campaign aims to elevate patient voices, provide resources on long-term decision-making and healthcare navigation, and encourage open dialogue among patients, caregivers, and clinicians.
TG Therapeutics (NASDAQ: TGTX) announced that multiple presentations on BRIUMVI (ublituximab) will be presented at the ACTRIMS annual forum in San Diego on Feb 6, 2026. Presentations include ENABLE real‑world infusion data and pediatric ULTIMATE KIDS I and II study designs.
Posters and ePosters are available on the company publications page and the ACTRIMS ePoster gallery.
TG Therapeutics (NASDAQ: TGTX) announced its schedule of BRIUMVI® (ublituximab-xiiy) data presentations at the ACTRIMS Annual Forum, Feb 5–7, 2026 in San Diego.
Multiple poster presentations cover real-world Phase 4 ENABLE infusion experience, pediatric dose-confirmation (ULTIMATE KIDS I) and Phase 3 comparative design versus fingolimod (ULTIMATE KIDS II), plus biomarker results from ENHANCE. Abstracts are available on the ACTRIMS website and detailed posters will be posted to the company Publications page after the meeting.
TG Therapeutics (NASDAQ: TGTX) reported preliminary unaudited results and 2026 guidance on Jan 13, 2026. Full year 2025 total global revenue is approximately $616 million, with BRIUMVI U.S. net product revenue of about $182 million in Q4 and $594 million for full year 2025. For 2026 the company targets $875–900 million in total global revenue, including $825–850 million of BRIUMVI U.S. net product revenue.
2026 operating expense target is ~$350 million (ex non-cash comp) plus ~$100 million for subcutaneous BRIUMVI inventory build and secondary manufacturer start-up. Key development milestones include pivotal topline ENHANCE mid‑2026, Phase 1 azer‑cel data H2 2026, and pivotal subcutaneous BRIUMVI data year‑end 2026/1Q 2027.